The clinical data supports this drug as a second line due to failure of first line & cheaper agents. Hospitals are also trying to control costs, and this drug does not fit well into that picture. If you do not know this, you do not know a thing about the hospital environment. Cost has been controlling the use of antibiotics for years now, everyone knows that.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
-
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
The clinical data supports this drug as a second line due to failure of first line & cheaper agents. Hospitals are also trying to control costs, and this drug does not fit well into that picture. If you do not know this, you do not know a thing about the hospital environment. Cost has been controlling the use of antibiotics for years now, everyone knows that.
Anonymous
Guest
Anonymous
Guest
Spoke with a N FL rep. Not all that he bargained for. Sorry, you are not long for this world.
Anonymous
Guest
Anonymous
Guest
If you did not know this before accepting an offer, then you did not do due diligence in investigating all the information that you posted which was out in the public domain. Having 10 years of hospital experience you know the challenges in the institutional environment, does not say much about your expertise, but that does not surprise anyone in the industry anymore. Too many people don't know a ____ thing about the products or company they go to work for. Its basic laziness.
How's your sales? Are you going for that promotion or are you the crazy DM that are harress rep? L
Anonymous
Guest
Anonymous
Guest
I'm having fun. Lots of interest and outpatient use. Hospitals are coming on board as expected. Just hope I get credit for the sales.
It's all about the bonus!
It's all about the bonus!
Anonymous
Guest
Anonymous
Guest
Marketing is full of bright, clueless people. Medical has some brilliant AI people
If they are so brilliant, why don't we have any publications to use? Why did they have to whore out to Cubist's MSLs instead of using our own?
Medical Affairs is a joke. We don't have any health economics information but we hired expensive help to lie about it.
I give this company two quarters to get more sales or the VC funds that own it will sell management out in a heartbeat.
Anonymous
Guest
Anonymous
Guest
If they are so brilliant, why don't we have any publications to use? Why did they have to whore out to Cubist's MSLs instead of using our own?
Medical Affairs is a joke. We don't have any health economics information but we hired expensive help to lie about it.
I give this company two quarters to get more sales or the VC funds that own it will sell management out in a heartbeat.
Agree. You stated all the reasons why start up fails.
Anonymous
Guest
Anonymous
Guest
If they are so brilliant, why don't we have any publications to use? Why did they have to whore out to Cubist's MSLs instead of using our own?
Medical Affairs is a joke. We don't have any health economics information but we hired expensive help to lie about it.
I give this company two quarters to get more sales or the VC funds that own it will sell management out in a heartbeat.
Have you ever launched a new drug before? Reprints are always scarce in the beginning. Selling with the PI only is typical. Verbalize your message!! Stop acting like a baby, need your baba!!
Anonymous
Guest
Anonymous
Guest
If you did not know this before accepting an offer, then you did not do due diligence in investigating all the information that you posted which was out in the public domain. Having 10 years of hospital experience you know the challenges in the institutional environment, does not say much about your expertise, but that does not surprise anyone in the industry anymore. Too many people don't know a ____ thing about the products or company they go to work for. Its basic laziness.
Sorry, but in most interviews people were told a lot of things that are not happening now. With all start ups people can only believe what they are told because there is nothing else to go by. I personally did not like being told there was no call reporting. This CATS is call reporting hell if you ask most in the sales force.
Anonymous
Guest
Anonymous
Guest
Sorry, but in most interviews people were told a lot of things that are not happening now. With all start ups people can only believe what they are told because there is nothing else to go by. I personally did not like being told there was no call reporting. This CATS is call reporting hell if you ask most in the sales force.
Hello, did you people do any investigation of this drug that was available in the public. Why would anyone expecet to get their information from any company, esp. one who has no experience in the hospital market to provide them with the bull____ that you know your going to get. The clinical data had already been published and reported as to how dificid was going to be utilized in the c.diff. market. Plus, anyone with antibiotic experience should know a thing or two about antibiotic utilization in the the hospital, how cost and evidence based medicine affects protocol placement and utilization. Companies should not hire reps. with no antibiotic hospital experience because the just don't have enough experience in this type of environment, becoming a knowledge expert takes years even for the smartest reps. (most don't care enough to know much of anything to be honest), and the impact of healthcare reform on drug usage/and access in the hospital. Everyone knows that hospital is not an easy job.
Anonymous
Guest
Anonymous
Guest
Been through this call recording story before. After CATS, we will have a witch hunt on the sales team regarding performance. Those who do not make their numbers (I don't mean sales) - reps who are not meeting the call recording numbers will be put on PIPs. It is a way management protect themselves form failure. Give it another 3 months, finger pointing will start. Reps will be blamed for under performance or promises to shareholders. DMs wilbrow on us to do more paper and reports to home office.
Anonymous
Guest
Anonymous
Guest
Hello, did you people do any investigation of this drug that was available in the public. Why would anyone expecet to get their information from any company, esp. one who has no experience in the hospital market to provide them with the bull____ that you know your going to get. The clinical data had already been published and reported as to how dificid was going to be utilized in the c.diff. market. Plus, anyone with antibiotic experience should know a thing or two about antibiotic utilization in the the hospital, how cost and evidence based medicine affects protocol placement and utilization. Companies should not hire reps. with no antibiotic hospital experience because the just don't have enough experience in this type of environment, becoming a knowledge expert takes years even for the smartest reps. (most don't care enough to know much of anything to be honest), and the impact of healthcare reform on drug usage/and access in the hospital. Everyone knows that hospital is not an easy job.
Hello, did you even read the post you replied to? That person was talking about the culture not the drug. Next time do your due diligence and read the post you are replying to before you speak.
Anonymous
Guest
Anonymous
Guest
Have you ever launched a new drug before? Reprints are always scarce in the beginning. Selling with the PI only is typical. Verbalize your message!! Stop acting like a baby, need your baba!!
Launched plenty of drugs before, how about you? Ever sold an antibiotic in a crowded market dominated by generics? Ever sold in a hospital?
The MSLs should have been out talking to docs after we got the PDUFA date. Management sat and did nothing about having the reprints available long after they were published.
There is a great deal of literature on the HEOR of C. dif. Our newly hired head of Medical Affairs came from Viropharma, who dominated the oral antibiotic market for the indication, and yet nothing - zip - zero - nada. They hired a bunch of know-nothings and had to reach out to Cubist to gain credibility. Cubist could care less and they are a lousy co-promote partner.
You should stop writing on this forum from your mommy's basement.
Anonymous
Guest
Anonymous
Guest
Our leaders in Jersey City expect us to read off the PI in selling to a hospital. It sound like a PC directions to me. The only thing that makes us hospital team is the we get slim jims and get to visit the pharmacists who tell us it is too expensive and no HOER data to support usage. Boy what a culture.
Anonymous
Guest
Anonymous
Guest
Anonymous
Guest
Anonymous
Guest
quit
Thank you. You just demonstrated the typical poor leadership style and the problem with this culture. You are the example why it is bad here.
Anonymous
Guest
Anonymous
Guest
Thank you. You just demonstrated the typical poor leadership style and the problem with this culture. You are the example why it is bad here.
Like I said...Quit
Dumbass
Anonymous
Guest
Anonymous
Guest
No. Here for the long run and will continue to share my thoughts.
Isold ABx so u r a retard!
Guest
Isold ABx so u r a retard!
Guest
Enough already with the "sold an antibiotic in the hospital" blah blah blah.
If you really think that GP and ML and the other managers and reps don't know the hospital or that antiobiotics are sooooo different give me an effin break.
This management group grew a product with NO superiority data, increased potential for bleeding, and a price 20x that of heparin (sounds like a lose/lose/lose situation right?) to an over $1 Billion indication on its own..so much so that the top targeted accounts had anywhere from $750,000 to $1M per yr in sales when the financial crisis hit.
Do you really think these reps and manager, who have 10+ years in pharma and at least 3 years and in many cases much more hospital experience, selling in the emergency room, cath lab, MICU/SICU/CCU,hematology, oncology, general and orthopedic surgery, the floors, etc don't know the game simply because they have not sold an antibiotic?
Try selling an interventional cardiologist to fly blind with Lovenox in the lab vs monitor UFH, or a CT surgeon to put up with a bloody field because Plavix was loaded in the ED, or the anticoagulation committee that just limited coags because of some ICH that would have happened anyway, or a P&T committee that can realistically save $150,000 yr with a switch to Fragmin post-financial crisis before you talk sh*t on the former SA management and reps.
Acute cardiovascular sales is highly complex because of the constellation of the comorbidities and special populations, +/- arrhythmia, +/-heart failure, +/-obese, +/-renal, +/-surgery, TIMI risk, CHADS scores, HASBLED scores, etc are all considerations from account to account. So don't tell us how antibiotic market place is sooooo complex that everyone with Abx experience is so incapable.
Congrats on having memorized the microbial taxonomy for key pathogens you are soooooo smarrrrrrrrrrrrrrrrrt.
If you really think that GP and ML and the other managers and reps don't know the hospital or that antiobiotics are sooooo different give me an effin break.
This management group grew a product with NO superiority data, increased potential for bleeding, and a price 20x that of heparin (sounds like a lose/lose/lose situation right?) to an over $1 Billion indication on its own..so much so that the top targeted accounts had anywhere from $750,000 to $1M per yr in sales when the financial crisis hit.
Do you really think these reps and manager, who have 10+ years in pharma and at least 3 years and in many cases much more hospital experience, selling in the emergency room, cath lab, MICU/SICU/CCU,hematology, oncology, general and orthopedic surgery, the floors, etc don't know the game simply because they have not sold an antibiotic?
Try selling an interventional cardiologist to fly blind with Lovenox in the lab vs monitor UFH, or a CT surgeon to put up with a bloody field because Plavix was loaded in the ED, or the anticoagulation committee that just limited coags because of some ICH that would have happened anyway, or a P&T committee that can realistically save $150,000 yr with a switch to Fragmin post-financial crisis before you talk sh*t on the former SA management and reps.
Acute cardiovascular sales is highly complex because of the constellation of the comorbidities and special populations, +/- arrhythmia, +/-heart failure, +/-obese, +/-renal, +/-surgery, TIMI risk, CHADS scores, HASBLED scores, etc are all considerations from account to account. So don't tell us how antibiotic market place is sooooo complex that everyone with Abx experience is so incapable.
Congrats on having memorized the microbial taxonomy for key pathogens you are soooooo smarrrrrrrrrrrrrrrrrt.
Anonymous
Guest
Anonymous
Guest
Enough already with the "sold an antibiotic in the hospital" blah blah blah.
If you really think that GP and ML and the other managers and reps don't know the hospital or that antiobiotics are sooooo different give me an effin break.
This management group grew a product with NO superiority data, increased potential for bleeding, and a price 20x that of heparin (sounds like a lose/lose/lose situation right?) to an over $1 Billion indication on its own..so much so that the top targeted accounts had anywhere from $750,000 to $1M per yr in sales when the financial crisis hit.
Do you really think these reps and manager, who have 10+ years in pharma and at least 3 years and in many cases much more hospital experience, selling in the emergency room, cath lab, MICU/SICU/CCU,hematology, oncology, general and orthopedic surgery, the floors, etc don't know the game simply because they have not sold an antibiotic?
Try selling an interventional cardiologist to fly blind with Lovenox in the lab vs monitor UFH, or a CT surgeon to put up with a bloody field because Plavix was loaded in the ED, or the anticoagulation committee that just limited coags because of some ICH that would have happened anyway, or a P&T committee that can realistically save $150,000 yr with a switch to Fragmin post-financial crisis before you talk sh*t on the former SA management and reps.
Acute cardiovascular sales is highly complex because of the constellation of the comorbidities and special populations, +/- arrhythmia, +/-heart failure, +/-obese, +/-renal, +/-surgery, TIMI risk, CHADS scores, HASBLED scores, etc are all considerations from account to account. So don't tell us how antibiotic market place is sooooo complex that everyone with Abx experience is so incapable.
Congrats on having memorized the microbial taxonomy for key pathogens you are soooooo smarrrrrrrrrrrrrrrrrt.
There is only one key pathogen, putz. It's not that difficult to remember.
Who cares if you sold into the acute cardiovascular market? You must have been one of the Scios crowd that got kicked out for going off label.
Selling antibiotics is different because there are only two other drugs used to treat C. dif. Both are much cheaper and have outcomes data that our brilliant management could not bother sharing with anyone.
It will take three or more years to break even with this drug. That is not a success, it's a failure.